131 related articles for article (PubMed ID: 11549207)
1. Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children.
Patoux A; Bleyzac N; Boddy AV; Doz F; Rubie H; Bastian G; Maire P; Canal P; Chatelut E
Eur J Clin Pharmacol; 2001 Jul; 57(4):297-303. PubMed ID: 11549207
[TBL] [Abstract][Full Text] [Related]
2. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin.
Thomas F; Séronie-Vivien S; Gladieff L; Dalenc F; Durrand V; Malard L; Lafont T; Poublanc M; Bugat R; Chatelut E
Clin Pharmacokinet; 2005; 44(12):1305-16. PubMed ID: 16372828
[TBL] [Abstract][Full Text] [Related]
3. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of carboplatin in children.
Chatelut E; Boddy AV; Peng B; Rubie H; Lavit M; Dezeuze A; Pearson AD; Roché H; Robert A; Newell DR; Canal P
Clin Pharmacol Ther; 1996 Apr; 59(4):436-43. PubMed ID: 8612389
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
Shen M; Schilder RJ; Obasaju C; Gallo JM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
[TBL] [Abstract][Full Text] [Related]
6. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
Peng B; Boddy AV; Cole M; Pearson AD; Chatelut E; Rubie H; Newell DR
Eur J Cancer; 1995 Oct; 31A(11):1804-10. PubMed ID: 8541105
[TBL] [Abstract][Full Text] [Related]
7. A sequential Bayesian algorithm for dose individualisation of carboplatin.
Duffull SB; Begg EJ; Robinson BA; Deely JJ
Cancer Chemother Pharmacol; 1997; 39(4):317-26. PubMed ID: 9025772
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.
Moeung S; Chevreau C; Broutin S; Guitton J; Lelièvre B; Ciccolini J; Massart C; Fléchon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Paci A; Marsili S; Malard L; Chatelut E; Thomas F
Clin Cancer Res; 2017 Dec; 23(23):7171-7179. PubMed ID: 28928162
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.
Etienne MC; Leger F; Pivot X; Chatelut E; Bensadoun RJ; Guardiola E; Renée N; Magné N; Canal P; Milano G
Ann Oncol; 2003 Apr; 14(4):643-7. PubMed ID: 12649114
[TBL] [Abstract][Full Text] [Related]
10. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.
Chatelut E; Pivot X; Otto J; Chevreau C; Thyss A; Renée N; Milano G; Canal P
Eur J Cancer; 2000 Jan; 36(2):264-9. PubMed ID: 10741287
[TBL] [Abstract][Full Text] [Related]
11. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.
Rousseau A; Sabot C; Delepine N; Delepine G; Debord J; Lachâtre G; Marquet P
Clin Pharmacokinet; 2002; 41(13):1095-104. PubMed ID: 12403645
[TBL] [Abstract][Full Text] [Related]
12. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer.
Johansen MJ; Madden T; Mehra RC; Wood JG; Rondon G; Browne V; Newman RA; Champlin RE
J Clin Oncol; 1997 Apr; 15(4):1481-91. PubMed ID: 9193344
[TBL] [Abstract][Full Text] [Related]
13. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy.
Rubie H; Doz F; Vassal G; Chastagner P; Gentet JC; Urien S; Bastian G; Drouard-Troalen L; Barberi-Heyob M; Catalin J; Chatelut E;
Eur J Cancer; 2003 Jul; 39(10):1433-8. PubMed ID: 12826047
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics and individual dose adjustment of carboplatin].
Chatelut E; Canal P; Bugat R
Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
[TBL] [Abstract][Full Text] [Related]
15. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
Schmitt A; Gladieff L; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Serre-Debauvais F; Pinguet F; Floquet A; Billaud E; Le Guellec C; Penel N; Campone M; Largillier R; Capitain O; Fabbro M; Houede N; Medioni J; Bougnoux P; Lochon I; Chatelut E
Clin Cancer Res; 2009 May; 15(10):3633-9. PubMed ID: 19401344
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic modelling of total and unbound plasma carboplatin--a population study in 75 children.
Urien S; Doz F; Namouni F; Bastian G
Int J Clin Pharmacol Ther; 2002 Jun; 40(6):270-8. PubMed ID: 12078941
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
Staatz CE; Tett SE
Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of two dose individualisation methods for carboplatin.
Desoize B; Dufour R; Urien S; Kaltenbach M; Colin P
Anticancer Res; 1996; 16(4A):2073-8. PubMed ID: 8712745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
